December 12, 2023 08:14 AM EST
R&D
FDA+

FDA sets late 2024 de­ci­sion dead­line for Pfiz­er’s 'pan-he­mo­phil­i­a' drug: #ASH23

Lei Lei Wu

News Reporter

SAN DIEGO — The FDA is ex­pect­ed to de­cide whether to ap­prove Pfiz­er’s he­mo­phil­ia A and B an­ti­body in the fourth quar­ter of 2024, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times